Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.
about
Recent advance in antigen-specific immunotherapy for acute myeloid leukemiaEvaluation of current cancer immunotherapy: hemato-oncologyImmune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cellsImpaired B cell immunity in acute myeloid leukemia patients after chemotherapy.Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotRepeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.Detection and preliminary characterization of CD8+T lymphocytes specific for Wilms' tumor antigen in patients with non-Hodgkin lymphoma.Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplantThe Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues.Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein.Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy.An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide.Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.Characterization of specific immune responses to different Aspergillus antigens during the course of invasive Aspergillosis in hematologic patientsCommon Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals.Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantationA Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing TumorsNew insights into antigen specific immunotherapy for chronic myeloid leukemiaAugmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.PRAME Gene Expression in Acute Leukemia and Its Clinical SignificanceThe preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.Dendritic cell-based immunotherapy for myeloid leukemias.Immunotherapy prospects for acute myeloid leukaemia.Immunotherapy of chronic myeloid leukemia: present state and future prospects.Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia.Vaccines as consolidation therapy for myeloid leukemia.Peptide vaccine therapy for leukemia.Is antigen specificity the key to efficient adoptive T-cell therapy?Antigens in chronic myeloid leukemia: implications for vaccine development.Expression of cancer-testis genes in brain tumors: implications for cancer immunotherapy.Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia.Current strategies in immunotherapy for acute myeloid leukemia.New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia.Do we need more drugs for chronic myeloid leukemia?Analogue peptides for the immunotherapy of human acute myeloid leukemia.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system.
P2860
Q27005765-0A869946-9057-436A-8AF1-870FC5170FC5Q27006179-3E9E1894-0BF0-45D4-B633-3724F0BB6E50Q33593877-8292DEE6-8D58-4CF8-9837-AF52F6729558Q33770125-1B943F19-82C8-481F-8D0C-806D325C2DD1Q33806895-374E8851-7524-482A-9C27-47447A80F647Q33892358-6579D0AF-A090-49DD-83C5-2A091C3F3216Q34180369-8F48AAC3-CA63-49EE-B247-16905F87BE54Q34612637-3B82249D-5359-4C7B-8A64-A7A7B61336F1Q34616701-B3B6B728-9F61-41E6-BF15-BA50A6D935DFQ34635978-17C3B2DF-8312-4C74-AD40-F8B094B0A0DFQ34750582-41FEACF8-8E13-4FDF-817F-59028D881546Q34792248-BB394307-D8D6-486B-A600-D8FB837B2008Q34803707-20FDC0A5-F438-4C7C-82F9-4525BFB01B1EQ34862104-3C77D6D0-311C-46B5-A788-A48ECCF72184Q34935239-E8EDB820-3823-44A3-9C57-19BD18B593CDQ34984670-B3490EFB-B84D-4FAB-9E2E-CAAF60B4F498Q35196739-0FF3547A-2E88-40D0-99E2-3D29135E5C5FQ35588845-D5FEEDF9-D1AC-4083-87C4-2221DB3FDD21Q36322371-E7C3169C-5DE6-4650-AE10-065B9828C143Q36513477-DEEDB7E9-329C-44F0-AFC8-2C1445F3C33DQ36662079-83D9573E-3EF4-4B08-B111-AC1B49B2C2DEQ36814310-3CFE3F16-25AB-4C2D-84E2-9C51A091734FQ37381700-DED8AD25-2B09-4829-A002-12A96B7E61DFQ37420778-0B621C42-3F4E-4EC8-A3C3-A5781920FF7FQ37763280-35F935B8-8DB9-4B04-A085-73FB7EFDE405Q37773256-03FC1367-D9EE-4DD7-AFA9-E2874ECF3B74Q37783631-65AA3D90-32A6-494A-8216-B810D60D178BQ37842342-E17B3056-0B3C-4A3D-B09A-6A9E4911578DQ37850382-A3103B5C-9F9B-4355-80A1-953FC6B62306Q37861214-5CFB56A4-0FA0-464B-8047-9A535CD17F39Q37950233-5A9225AC-BFBF-4686-94C5-BC1C2D46A5C6Q37965751-D0F3552F-DED8-4B5D-9508-EB09458A7B25Q38015123-FFE647E5-536B-4416-895C-5BD29399222BQ38068967-F71DD70E-B26A-4DB2-9685-B6D18D77BD58Q38245928-60C255FD-B5F7-4E29-A5E9-311808D20C58Q38289033-2F6042C9-2DAC-46ED-A020-08DB3F92452EQ38599586-898A1974-34A9-4579-953C-1F38CBBD2ABDQ38664735-549B09E7-9B4F-4C14-A5F4-D6E16F949CFDQ38719407-56BE9BA4-2133-4F1D-A549-650CDEA7EB3BQ39108154-1AB85277-B7E8-4F4B-BD89-E98C0943DE62
P2860
Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Ex vivo characterization of po ...... and chronic myeloid leukemia.
@en
Ex vivo characterization of po ...... and chronic myeloid leukemia.
@nl
type
label
Ex vivo characterization of po ...... and chronic myeloid leukemia.
@en
Ex vivo characterization of po ...... and chronic myeloid leukemia.
@nl
prefLabel
Ex vivo characterization of po ...... and chronic myeloid leukemia.
@en
Ex vivo characterization of po ...... and chronic myeloid leukemia.
@nl
P2093
P2860
P921
P1433
P1476
Ex vivo characterization of po ...... e and chronic myeloid leukemia
@en
P2093
A John Barrett
Abdul Tawab
Behnam Jafarpour
Bipin N Savani
Katayoun Rezvani
Keyvan Keyvanfar
Rhoda Eniafe
Roger Kurlander
P2860
P304
P356
10.1182/BLOOD-2008-03-144071
P407
P577
2008-11-06T00:00:00Z